Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035 ...

Insmed (INSM) saw a significant price move of 87% over the past quarter, driven by pivotal product developments and regulatory milestones. The FDA's approval of BRINSUPRI as the first oral treatment ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...